指南与共识放疗物理与技术姑息放疗与转移瘤

放射肿瘤环境下放射性药物治疗的质量与安全考量:ASTRO安全白皮书

Quality and Safety Considerations for Radiopharmaceutical Therapy in the Radiation Oncology Environment: An ASTRO Safety White Paper.
指南 / 共识 · Pract Radiat Oncol · 2025-04-04

本白皮书聚焦在放射肿瘤科建立和维持放射性药物治疗(RPT)项目的后勤与安全流程,涵盖α和β发射体。ASTRO组织多学科工作组,采用共识构建方法和5点Likert量表(预设≥75%同意为共识)形成建议。内容涉及基础设施、多学科协作、质量管理、事件报告和外部审计等。

要点

  • 建立RPT项目需具备接收、储存、制备和给药的基础设施及特定输注技术的人员。
  • RPT病例受益于由放射肿瘤医生和授权用户领导的多学科方法。
  • 需制定全面质量管理计划以符合法规和标准,并鼓励参与事件报告和外部审计。

核心结论

  • 使用本指南,授权用户可评估开展RPT项目的可行性、开发必要基础设施并维持安全高质量的RPT项目。

研究设计与样本

  • ASTRO召集由放射肿瘤学、核医学、医学和健康物理专家组成的多学科工作组。
  • 建议采用共识构建方法,成员基于5点Likert量表(从「非常同意」到「非常不同意」)表示同意程度。
  • 预设≥75%的评分者选择「非常同意」或「同意」即表示达成共识。
  • 未达到此阈值的内容被删除或修订。

关键数值与推荐

  • 共识阈值:≥75%的评分者选择「非常同意」或「同意」。

临床怎么用

  • 建立RPT项目需特定基础设施用于接收、储存、制备和给药,并由具备特定输注方法专长的人员操作。
  • RPT病例受益于由放射医学医生和授权用户领导、经RPT培训的其他人员支持的多学科方法。
  • 必须制定全面质量管理计划以符合适用法规和标准,包括放射性材料的处理。
  • 鼓励参与事件报告和对实践整体质量保证过程的外部审计。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiopharmaceutical therapy (RPT) is the latest topic in a series of white papers published by ASTRO addressing quality processes and patient safety. The availability of radiopharmaceutical agents for therapeutic use has broadened patient treatment options; although generally administered systemically, their effects are targeted to cellular receptors or the tumor microenvironment. Radiation oncology is well suited to delivering RPT because clinicians are already experienced in radiation safety, treatment delivery, and ongoing patient care. This paper focuses on the logistics of initiating and/or maintaining an RPT program in radiation oncology and includes collaborating with other medical specialties. The white paper addresses the safety processes and workflow considerations for alpha- and beta-emitting radionuclides used for RPT. METHODS: ASTRO convened a multidisciplinary task force, composed of experts from radiation oncology, nuclear medicine, medical and health physics, to provide consensus on key workflows and processes for RPT. Recommendations were created using a consensus-building methodology and task force members indicated their level of agreement based on a 5-point Likert scale, from "strongly agree" to "strongly disagree." A prespecified threshold of ≥75% of raters who select "strongly agree" or "agree" indicated consensus. Content not meeting this threshold was removed or revised. SUMMARY: Establishing an RPT program in radiation oncology requires specific infrastructure for receiving, storing, preparing, and administering radiopharmaceuticals by staff with expertise in specific infusion methods. RPT cases benefit from a multidisciplinary approach led by a radiation medicine physician and authorized user with support from additional personnel trained in RPT. A comprehensive quality management program must be developed to comply with applicable regulations and standards, including the handling of radioactive materials. Participation in incident reporting and external audits of a practice's overall quality assurance processes is encouraged. Using the guidance provided, authorized users can assess the viability of starting an RPT program, develop the necessary infrastructure, and sustain a safe, high-quality RPT program that includes radiation oncology.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zoberi JE, Charara Y, Clements J, et al. Quality and Safety Considerations for Radiopharmaceutical Therapy in the Radiation Oncology Environment: An ASTRO Safety White Paper. Pract Radiat Oncol. 2025. PMID: 40366324. doi:10.1016/j.prro.2025.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。